Cell-based models for human diseases

Cell-based assay technology reagents

Citation Spotlight: Tempo-iCardio™ and Tempo-iCort™ in a Nonclinical CAR-Treg Therapy Safety Study

Tempo-iCardio™ and Tempo-iCort™ were cited recently in Toxicological Sciences in a study investigating the nonclinical safety of SBT777101, a novel chimeric antigen receptor-regulatory T-cell (CAR-Treg) therapy developed by Sonoma Biotherapeutics for inflammatory conditions, including rheumatoid arthritis and hidradenitis suppurativa. The researchers, based at Sonoma Biotherapeutics and Aclairo Pharmaceutical Development Group, incorporated Tempo-iCort™ human iPSC-derived cortical neurons and Tempo-iCardio™ human iPSC-derived cardiomyocytes into a panel of human cell types to assess potential unintended CAR binding, Treg activation and cytotoxicity. The study highlights how human...

Biomarkers: What Does the Data Really Tell Us?

Biomarker measurements provide valuable information about biological processes, disease and treatment response, but they represent selected features of a much more complex biological system. Many biomarker assays provide a time-fixed snapshot. DNA, RNA and protein...

read more

Where Do NAMs Fit in Drug Development?

In our last article, we explored how selecting the right model depends on the scientific question and the stage of research. We summarized the strengths and limitations of animal- and human-derived cells and discussed why moving toward more human-relevant models is...

read more

Tempo Bioscience Services

Disease Models and Assay Services

Tempo offers services and alliances based on our advanced technological platforms and a range of capabilities. Our team differentiates ourselves based on a strong commitment to innovative solutions and quality R&D for our partners.

Tempo Bioscience Support

On Demand Custom Engineered Cell Models

Tempo develops patient relevant stem cell (iPSCs) based models to support drug discovery, preclinical studies, and early-stage clinical development.